跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2006-006748-76-BE
EUCTR2006-006748-76-BE进行中（未招募）不适用

A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/A

Pfizer Ltd, Ramsgate Road, Sandwich, Kent UK0 个研究点目标入组 219 人开始时间: 2008年1月29日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
入组人数
219
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Subjects aged 18 and over with any of the following conditions:
  • •Idiopathic Primary Pulmonary Arterial Hypertension (IPAH)
  • •PAH secondary to connective tissue disease
  • •PAH with surgical repair (at least 5 years previously) of atrial septal defect (ASD),
  • •ventricular septal defect (VSD), patent ductus arteriosus (PDA) and aorto-pulmonary
  • •2. Subjects with a mean pulmonary artery pressure of =25 mmHg and a pulmonary artery wedge pressure of =15 mmHg at rest (or in the event that PAWP is unobtainable, a left ventricular end diastolic pressure (LVEDP) of <14 mmHg and absence of any mitral stenosis on echocardiography) via right heart catherization performed within 12 weeks prior to randomization. Subjects who underwent right heart catheterization and who fulfil the following criteria:
  • •background therapy (class and dose of drug) has not been changed for at least 30 days prior to right heart catheterization measurement,
  • •the drugs and doses used for background therapy have not changed since
  • •catheterization for inclusion (subjects can undergo repeat right heart catheterization
  • •prior to randomization).
  • •3. Subjects whose baseline 6MWT distance is =100 m and =450 m.
  • •4. If you are a woman of childbearing potential you are not allowed to be pregnant before participating in the study. The screening urine pregnancy test must be negative (if the urine pregnancy test is positive, a serum pregnancy test should be performed and the result should be negative). You must use either birth-control pills, coil, gestagen depot injection, sub dermal implant, vaginal hormone ring or transdermal patch as contraception throughout the whole study. In addition to that, contraception must be used for four weeks after completion of the study. Women who have been surgically sterilized or are at least two years postmenopausal may be enrolled and do not need to use birth control.
  • •5. Subjects who are willing and able to comply with scheduled visits, treatment plan,
  • •laboratory tests, and other trial procedures.
  • •6. Subjects who have been informed of all pertinent aspects of the trial and have given (personally signed and dated) written informed consent to participate in the study before being screened for the study.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1. PAH secondary to any aetiology including congenital heart disease other than those specified in the inclusion criteria.
  • •2. Subjects with significant (i.e.> 2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation. Subjects with previous surgical replacement of a valve may be eligible for entry into the study after consultation with a Pfizer study clinician provided the following conditions are satisfied:
  • •That there was no evidence of PAH secondary to valvular disease prior to surgery
  • •The prosthetic valve is functioning normally on echocardiography
  • •The valve replacement occurred at least one year prior to screening.
  • •3. Subjects who have undergone atrial septostomy within 6 months prior to randomization (subjects who are required to undergo this procedure during the study should be withdrawn).
  • •4. Subjects with acutely decompensated heart failure within the previous 30 days prior to screening.
  • •5. Subjects with a left ventricular ejection fraction less than 40% or LV shortening fraction <0.2 within 3 months prior to randomization.
  • •6. Subjects with acute myocardial infarction within 3 months prior to randomization.
  • •7. Subjects with uncontrolled brady- or tachyarrhythmias (e.g. sinus arrest, complete heart block, atrial fibrillation or flutter, frequent runs of ventricular tachycardia); placement of dual chamber pacemakers and/or implantable defibrillators <60 days prior to randomization.
  • •8. Subjects whose 6 Minute Walk Distance may be limited by conditions other than PAH related dyspnoea or fatigue, e.g. claudication from vascular insufficiency or significant arthritis.
  • •9. Subjects who are currently receiving any forms of chronic treatment for PAH such as prostacyclin, PDE-5 inhibitors, endothelin-receptor antagonists, nitrates or nitric
  • •oxide donors (e.g. arginine supplement, nicorandil) in any form, protease inhibitors
  • •such as ritonavir and saquinavir, ketoconazole, itraconazole and alpha blockers. Subjects previously receiving any of these drugs must have stopped use for a period of at least 1 month prior to screening.
  • •10. Subjects who have previously failed on chronic treatment with sildenafil therapy (defined as those subjects who had no improvement and no change in symptoms on
  • •discontinuation of the medicine).
  • •11. Subjects who have had a change of dose or class of standard background therapy used for treatment of PAH (e.g. oxygen, calcium channel blockers, digoxin, diuretics) within 30 days prior to randomization. Exception is treatment with anticoagulants where a patient’s dose may need to be adjusted based on INR.
  • •12. Pregnant or lactating women.
  • •13. Subjects with a history of pulmonary embolism verified by ventilation/perfusion scan, angiogram or spiral chest CT scan.
  • •14. Subjects with known hereditary degenerative retinal disorders (such as retinitis
  • •pigmentosa) or history of non-arteritic anterior ischaemic optic neuropathy.
  • •15. Subjects with history of chronic lung diseases / restrictive lung disease (e.g. chronic obstructive pulmonary disease (COPD) or scleroderma) with impairment of lung function if total lung capacity (TLC) <60% predicted within 30 days of randomization.
  • •16. Subjects at screening with impairment of renal function (serum creatinine >2.5 mg/dL (>220 µmol/L)). This criterion may be satisfied by a creatinine result from the clinic’s local laboratory.
  • •17. Subjects with hypotension defined as systolic arterial pressure <90 mmHg after sitting for 5 minutes at either screening or b

研究者

发起方
Pfizer Ltd, Ramsgate Road, Sandwich, Kent UK

相似试验

进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)
EUCTR2006-006748-76-BGPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK219
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/A
EUCTR2006-006748-76-GRPfizer Ltd. Ramsgate Road, Sandwich, Kent, UK284
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH).MedDRA version: 8.1Level: LLTClassification code 10037400Term: Pulmonary hypertension
EUCTR2006-006748-76-NLPfizer Ltd. Ramsgate Road, Sandwich, Kent, UK284
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)
EUCTR2006-006748-76-DKPfizer Ltd, Ramsgate Road, Sandwich, Kent UK219
进行中（未招募）
1 期
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)
EUCTR2006-006748-76-GBPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK219